Prima signs first licence deal for CVac
Prima Biomed (ASX:PRR) has finalised the terms for its first licensing deal for cancer treatment candidate CVac, signing an agreement with Israeli distributor Neopharm.
Under the terms of the deal, announced in November, Prima and Neopharm will split net profits from any CVac sales in Israel.
Prima will also receive reimbursement for the commercial manufacturing costs of CVac and small milestone payments over the commercialisation process.
“I am very pleased we were able to finalise our licence agreement with Neopharm, which is our first corporate partnership for CVac,” Prima CEO Matthew Lehman said. “Neopharm has gained a reputation for its ... performance marketing drugs manufactured by leading global companies.”
CVac is a personalised vaccine designed to stimulate the immune system to target and destroy tumours. It is derived from a patient’s own dendritic cells, treated with mucin 1 fused to mannan.
CVac is in phase II trials for the treatment of epithelial ovarian cancer in remission, and Prima is preparing to commence a pilot trial in resected pancreatic cancer.
Prima Biomed (ASX:PRR) shares were trading unchanged at $0.049 as of around 2 pm on Tuesday.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
